A research posted in JAMA Community Open emphasizes the discrepancy among what it expenditures to supply copyright plus the retail rates patients facial area. Regardless of the minimal output charges, Novo Nordisk hasn't publicly disclosed distinct figures for copyright or its other product or service, Wegovy.In October 2024, Novo Nordisk published